Cardarine peptide

The most consequential detail about GW-501516 is not what it does in muscle cells — it's why its clinical development was terminated. In preclinical studies across multiple species, prolonged exposure to Cardarine accelerated cancer development in tissues as diverse as the liver, bladder, stomach, tongue, and skin, a toxicity signal strong enough to halt all human trials and trigger regulatory warnings that remain in effect today.

Why Cardarine Is Not a SARM Despite the Name

GW-501516, commonly sold as Cardarine or GW1516, is a synthetic PPARδ agonist — not a selective androgen receptor modulator. The confusion comes from market positioning, not biology. PPARδ (peroxisome proliferator-activated receptor delta, also written PPARβ/δ in some literature) belongs to the nuclear receptor superfamily, a class of ligand-activated transcription factors that regulate gene expression. It has no structural relationship to androgen receptors and does not bind testosterone or its analogs.

GlaxoSmithKline and Ligand Pharmaceuticals developed GW-501516 in the early 2000s as part of a program targeting metabolic syndrome, dyslipidemia, and cardiovascular disease. The compound's molecular weight is 453.49 Da, and its structure (C₂₁H₁₈F₃NO₃S₂) includes a thiazole ring and a trifluoromethyl group engineered for receptor selectivity. Early rodent work showed promising effects on lipid metabolism and exercise endurance, which led to Phase I and Phase II human trials. Those trials ended in 2007 when preclinical toxicology flagged tumor promotion across multiple organ systems — a finding that permanently removed Cardarine from legitimate clinical development.

Despite regulatory warnings from the FDA and WADA, the compound remains available through grey-market research chemical suppliers and is frequently discussed in performance enhancement communities, often under the misleading label of a SARM.

How PPARδ Activation Shifts Cellular Fuel Utilization

GW-501516 binds with high affinity to PPARδ, which is expressed at particularly high levels in skeletal muscle, cardiac muscle, adipose tissue, and the brain. Once bound, the receptor undergoes a conformational change that allows it to heterodimerize with the retinoid X receptor (RXR), translocate to the nucleus, and bind to peroxisome proliferator response elements (PPREs) in the promoter regions of target genes.

This transcriptional activation upregulates genes involved in fatty acid oxidation, mitochondrial biogenesis, and oxidative metabolism. Key downstream targets include carnitine palmitoyltransferase 1 (CPT1), the rate-limiting enzyme for fatty acid entry into mitochondria, and pyruvate dehydrogenase kinase 4 (PDK4), which suppresses glucose oxidation and shifts the cell toward lipid-based fuel. The net metabolic effect is a preference for burning fat over glucose — a shift most pronounced in slow-twitch oxidative muscle fibers.

PPARδ also modulates inflammatory pathways. Activation can suppress NF-κB-driven inflammatory gene expression in macrophages and endothelial cells, which has made it a target of interest in atherosclerosis and neuroinflammation research. The receptor's tissue distribution and gene targets explain the observed phenotypes in animal models: improved endurance capacity, altered lipid profiles, and potential anti-inflammatory effects.

What Rodent and Human Studies Actually Show — And What They Don't

The published literature on GW-501516 is split sharply between efficacy data in animals and toxicology findings that ended human development.

In sedentary and exercise-trained mice, GW-501516 treatment increased running endurance by 68% and 75%, respectively, in studies from the Salk Institute published in 2008. These animals showed increased expression of genes associated with oxidative metabolism in skeletal muscle and a fiber-type shift toward oxidative myofibers. Separate rodent work demonstrated dose-dependent improvements in HDL cholesterol, reductions in triglycerides, and decreased liver fat accumulation in diet-induced obesity models. These findings matched the compound's mechanism and supported its original metabolic disease indication.

Human data is far more limited. A 2007 Phase II trial in dyslipidemic patients (n=268) showed dose-dependent increases in HDL cholesterol and reductions in triglycerides and LDL over 12 weeks. Doses ranged from 2.5 mg to 10 mg daily. The trial did not assess exercise performance, body composition, or fat oxidation in humans. No peer-reviewed publication from this trial exists in the public domain — the primary source is a discontinued clinical trial registry entry.

Development stopped because of carcinogenicity signals in long-term rodent toxicology studies. In a two-year rat study, animals treated with GW-501516 at multiple dose levels showed statistically significant increases in adenomas and carcinomas in the liver, bladder, stomach, skin, tongue, testes, ovaries, and thyroid. Tumor development occurred at doses intended to model therapeutic exposure in humans. Similar findings emerged in mice. The mechanism is thought to involve sustained activation of proliferative pathways in susceptible cell populations, though the exact molecular trigger for tumorigenesis remains incompletely characterized.

There are no published long-term human safety studies, no Phase III trials, and no controlled data on performance outcomes in human athletes. The compound is prohibited by the World Anti-Doping Agency and has been the subject of multiple FDA and international regulatory warnings.

Dosing, Half-Life, and Practical Research Considerations

Published research uses dosing ranges that vary by species and objective. In mice, efficacy studies typically used 5-10 mg/kg/day administered orally. In the human dyslipidemia trial, doses ranged from 2.5 mg to 10 mg per day in divided doses. Grey-market sources often recommend 10-20 mg daily in humans, but these protocols are not derived from controlled clinical data and carry unknown risk.

GW-501516 has an estimated half-life of 16-24 hours in humans based on pharmacokinetic modeling from early-phase trials, though peer-reviewed PK data remains sparse. Oral bioavailability appears sufficient to produce systemic receptor activation, which aligns with its original development as an oral therapeutic agent. Stability data from research suppliers typically specifies storage at -20°C in powder form, with reconstituted solutions stable for limited periods under refrigeration — though these recommendations are not standardized and product quality varies widely across suppliers.

Drug interaction studies in humans are essentially absent. Mechanistically, PPARδ activation could interact with other metabolic or lipid-modulating agents, and its effects on gene transcription suggest potential for interactions with drugs metabolized through pathways it regulates. For research purposes only, any use in experimental settings should account for the absence of established safety margins and the documented carcinogenicity signal.

Analytical detection is possible via liquid chromatography-mass spectrometry, and WADA-accredited labs routinely test for GW-501516 metabolites. Detection windows extend several weeks after cessation based on anti-doping case reports.

FAQ

Q: Is Cardarine actually a peptide?

No. Cardarine (GW-501516) is a small-molecule synthetic compound, not a peptide. It is frequently grouped with research peptides and SARMs in online communities, but it contains no amino acid backbone and does not share structural features with peptides. It is a PPARδ receptor agonist with a molecular weight of 453.49 Da.

Q: Why was Cardarine pulled from clinical trials if it worked in animals?

GW-501516 was discontinued after two-year toxicology studies in rats and mice showed a clear dose-dependent increase in cancer incidence across multiple organ systems, including the liver, bladder, stomach, and thyroid. The tumor promotion was reproducible and occurred at doses relevant to human therapeutic use, making further clinical development untenable from a risk-benefit perspective.

Q: Are there safer alternatives that work through the same mechanism?

No FDA-approved PPARδ agonists exist for clinical use. Some research groups are investigating next-generation PPARδ modulators with altered selectivity profiles, but none have progressed through human trials. Endurance and metabolic benefits observed with GW-501516 in animals have not been safely replicated in humans with any pharmacological agent targeting this pathway.

Q: How long does GW-501516 stay detectable in drug tests?

Based on anti-doping case reports and WADA documentation, GW-501516 metabolites can be detected in urine via LC-MS/MS for approximately 3-4 weeks after the last dose, though detection windows vary with dose, duration of use, and individual metabolism. It remains on WADA's prohibited substance list and is regularly tested for in competitive sports.

Q: Does the cancer risk apply to short-term use?

Unknown. The carcinogenicity signal emerged from chronic exposure studies lasting months to years in rodents. No controlled data exist on cancer risk from shorter exposures in any species, and the threshold dose or duration required for tumor promotion has not been established. The absence of long-term human data means that even short-term risk cannot be characterized with confidence.

This article is for informational and educational purposes only. GW-501516 is not approved for human use by any regulatory authority, and its use is associated with serious and documented long-term toxicity in animal models. This content does not constitute medical advice, and no statements herein should be interpreted as endorsing or recommending the use of this compound.